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Abstract: Motor neuron diseases (MNDs) are neuromuscular disorders affecting rather 
exclusively upper motor neurons (UMNs) and/or lower motor neurons (LMNs). The 
clinical phenotype is characterized by muscular weakness and atrophy leading to paralysis 
and almost invariably death due to respiratory failure. Adult MNDs include sporadic and 
familial amyotrophic lateral sclerosis (sALS-fALS), while the most common infantile 
MND is represented by spinal muscular atrophy (SMA). No effective treatment is 
ccurrently available for MNDs, as for the vast majority of neurodegenerative disorders, and 
cures are limited to supportive care and symptom relief. The lack of a deep understanding 
of MND pathogenesis accounts for the difficulties in finding a cure, together with the 
scarcity of reliable in vitro models. Recent progresses in stem cell field, in particular in the 
generation of induced Pluripotent Stem Cells (iPSCs) has made possible for the first time 
obtaining substantial amounts of human cells to recapitulate in vitro some of the key 
pathogenetic processes underlying MNDs. In the present review, recently published studies 
involving the use of iPSCs to unravel aspects of ALS and SMA pathogenesis are discussed 
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with an overview of their implications in the process of finding a cure for these still  
orphan disorders. 
Keywords: induced pluripotent stem cells; amyotrophic lateral sclerosis; spinal muscular 
atrophy; disease modeling 
 
1. Introduction 
Motor Neuron Diseases (MNDs) are incurable neurological disorders characterized by the 
progressive loss of pyramidal cells in the primary motor cortex (upper motor neurons, UMNs) and/or 
cells in the anterior horns of the spinal cord and their homologues in the motor nuclei of the brainstem 
(lower motor neurons, LMNs). Concerning their epidemiology, the prevalence of MNDs accounts for 
about 5–7 cases in every 100,000 people, with an annual incidence of approximately two new cases 
per 100,000 people [1]. MNDs are not equally distributed between genders, being more common in 
males, with a male to female ratio of 2:1 [1]. There is a great variability in life expectancy of patients 
affected by MNDs, for reasons that remain unknown for the most part: death usually occurs within  
3–5 years after the onset of symptoms (such as for amyotrophic lateral sclerosis—ALS), but cases with 
either a slower (i.e., spinobulbar muscular atrophy—SBMA) or a more rapid course have been 
described (i.e., spinal muscular atrophy—SMA type 1) [2]. 
The biological substrate of MNDs is responsible for the extremely disabling clinical phenotype, 
characterized by progressive weakness with muscle wasting, eventually leading to paralysis and death, 
mostly secondary to respiratory insufficiency [3]. No effective therapy is currently available and the 
only possible treatments are limited to palliative care. Besides affecting life expectancy, MNDs highly 
impact on patients’ quality of life: they are usually dependent on the use of respiratory aids and 
wheelchairs, requiring 24-h assistance [4]. 
MNDs are usually differentiated relating to the subset of motor neurons that are mainly involved in 
the disease course. Upper motor neurons are especially affected in primary lateral sclerosis (PLS) and 
hereditary spastic paraplegias (HSP). On the other hand, SMA, progressive muscular atrophy (PMA), 
SBMA and hereditary motor neuropathies (HMNs) involve mainly lower motor neurons. 
ALS is the most common adult form of MND, characterized by the simultaneous degeneration of 
UMNs and LMNs. ALS can be divided into a sporadic form (sALS), representing 90%–95% of all 
cases, and a familial form (fALS), accounting for the remaining 5%–10% of cases [5]. It is well 
accepted that genetic factors play a determinant role also in the sporadic ALS cases [6]. The sporadic 
form presents a rather uniform distribution in Western countries: in Europe and North America, the  
incidence is 1.5–2.7 cases per 100,000 persons every year [5], with a prevalence of 2.7–7.4 cases per 
100,000 persons [7]. The incidence increases considerably every decade of life, reaching a peak at  
74 years of age, and then progressively decreases [8]. The lifetime risk to develop ALS is 1:350 for 
males and 1:400 for females [9]. The age of onset is around 50–60 years, and the mean survival of 
ALS patients is 2–3 years after the diagnosis. 5%–10% of patients affected by ALS have a familial 
history of MNDs (fALS), in most cases presenting a mendelian autosomal dominant pattern of 
inheritance [6]. The clinical phenotype of fALS is usually considered indistinguishable from sALS. 
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Nevertheless, fALS is characterized by an equal male to female ratio, a more precocious age of onset 
and, oftentimes, a longer life expectancy. At present, more than 16 loci have been associated with ALS 
or other atypical forms of MNDs, and two loci have been associated to ALS with frontotemporal 
dementia (ALS-FTD) [6]. In about 60% of fALS patients, a causative gene can be identified. 
Mutations of C9ORF72 are found in 40% of cases, followed by mutations of superoxide dismutase-1 
(SOD1) (20% of cases), TARDBP (4% of cases), FUS (4% of cases) and other genes [10]. 
The group of SMAs comprises a series of LMN disorders characterized by extreme heterogeneity in 
both clinical presentation and genetic condition. 
The most prevalent forms of SMAs go under the name of “Proximal Spinal Muscular Atrophy”, 
often referred to simply as “SMA”, and are caused by genetic mutations on chromosome 5q (hence  
the term “5q-SMA”). SMA is the most common MND during childhood: with an incidence of  
1:6000–1:10,000 live births and a carrier frequency of 1:40–1:60, it is the leading genetic cause of infantile 
mortality [11,12]. SMA selectively affects LMNs, being characterized by the degeneration of alpha 
MNs in the ventral horns of the spinal cord and MNs in the motor nuclei of cranial nerves in the 
brainstem. SMA patients exhibit a progressive and symmetric involvement of various muscle groups, 
which present hypotonic, hyposthenic and atrophic, with a preferential distribution in the proximal 
compartments of the lower limb. Based on the degree of severity of the disease, different forms of 
SMA can be identified (types I–IV). Children with type I SMA, the most severe and common form, 
are affected at birth or, at the latest, by the age of 6 months, thus never becoming able to sit [13]. The 
other types of SMA present a progressively milder phenotype. Life expectancy is extremely variable in 
the spectrum of the different forms of the disease, ranging from less than 2 years of age in type I, to an 
unaffected lifespan in type IV. The genetic condition accounting for the disease displays homozygous 
deletions or mutations of the survival motor neuron (SMN) gene mapped in 5q11.2–q13.3 [14]. In the 
human genome, two almost identical copies of SMN are localized on chromosome 5q13: the telomeric 
SMN1 gene and its inverted centromeric homologue SMN2. SMN2 only differs from SMN1 for five 
base pair changes, of which a C to T substitution at +6 of exon 7 (c.840C > T) is the only nucleotide 
change in the coding region [15]. This is localized in an exonic splicing enhancer, thus causing an 
alternative splicing of pre-mRNA of SMN2 that excludes exon 7 from the majority of SMN2 
transcripts. The result is the production of 10%–50% of the full-length functional protein and  
50%–90% of a truncated, non-functional and unstable transcript (SMNΔ7) [16]. All individuals 
affected by SMA retain a variable number of copies of SMN2, which correlates to the severity of the 
disease. The exact functions of the SMN protein, as much as the reasons accounting for the disruption 
of MNs in SMA, are yet to be fully disclosed. 
Further, less common forms of SMAs recognize defects in genes other than SMN1 and present with 
early denervation weakness, but different clinical symptoms than those stated above, including joint 
contractures (infantile SMA with arthrogryposis—XL-SMA), distal rather than proximal weakness 
(distal SMA or HMNs), diaphragmatic paralysis (SMA with respiratory distress 1—SMARD1), and 
pontocerebellar degeneration (SMA with pontocerebellar hypoplasia—SMA-PCH) [17,18]. 
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The inaccessibility to the cell type of interest majorly involved in MNDs and the lack of established 
models for the elucidation of pathogenetic mechanisms underlying such disorders represent a 
fundamental obstacle for progresses to be made in the field of therapies development. In order to 
resolve these issues and make durable discoveries, new strategies should be taken into account. In this 
respect, stem cell technology may represent a valuable solution. 
Induced pluripotent stem cells (iPSCs) are originated from patients’ differentiated cells (oftentimes 
fibroblasts) through the use of reprogramming factors, first identified by Yamanaka in 2006 [19]. 
IPSCs are able to differentiate towards cell types of the three germ layers in vitro and give rise to 
teratomas in vivo. They can be identified with stem cell markers and resemble embryonic stem cells 
(ESCs) both in morphology and behaviour, but they are not burdened by ethical concerns [20]. IPSCs 
are patients’ specific cells, thus avoiding more likely immunoreactions if transplantation strategies 
were taken into account. Moreover, iPSCs can be produced in substantial amounts, providing an 
optimal cell source for regenerative therapeutic approaches. The possibility of differentiating iPSCs 
towards any cell type of interest represents a great advantage in the context of MNDs, which affect 
MNs rather selectively [21]. Indeed, in recent years, protocols for the differentiation of iPSCs towards 
MNs have been developed and optimized, since obtaining human relevant cells appears pivotal for the 
development of in vitro models that recapitulate mechanisms responsible for the establishment of 
pathologies [21]. Obtained results could be crucial in guiding the process of finding an effective 
treatment for ALS, SMA and other MNDs. Fibroblasts can be easily obtained from skin biopsies and 
grown in culture, thus making the premises for a simple disease model [22]. Furthermore, MNDs with 
a genetic background may benefit from in vitro models obtained from iPSC-derived differentiated 
cells, like iPSC-MNs, exhibiting the affected genotype peculiar to the disease. So far, the great potential 
of iPSCs led to the generation of patient-specific cells for several neurodegenerative disorders, 
including Alzheimer’s Disease [23], Huntington’s Disease [24], Parkinson’s Disease [25] and 
Amyotrophic Lateral Sclerosis [26]. These considerations suggest that iPSCs could be the key to 
unravel pathogenetic processes behind human diseases which are challenging to study in the animal 
models for their specific features (Figure 1). Obtained results may pave the way to the development of 
effective treatments targeting specific disease mechanisms. Here, we review the recent advances in  
the field of iPSCs as regards their use in modeling and studying MNDs, with a focus on ALS and 
SMA pathogenesis. 
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Figure 1. iPSC-based platforms for motor neuron disease modeling. Patients-derived 
somatic cells can be reprogrammed into iPSCs. Obtained cells can be differentiated 
towards the subtype of interest and studied in their development. Further analyses include 
the investigation of the transcriptional profile and the elucidation of molecular pathogenetic 
pathways. Human iPSCs are also a valuable tool for the identification of molecular targets 
and the screening of potential therapeutic compounds. 
 
2. Modeling and Studying Amyotrophic Lateral Sclerosis Using IPSCs 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with adult onset. 
Symptoms reflect the dysfunction and death of motor neurons (MNs) and are characterized by 
muscular weakness and atrophy progressively leading to paralysis [27]. Upper and lower MNs appear 
to be particularly vulnerable to the disease process since they are the most relevant affected cells in the 
context of a relative sparing of other neuronal populations [28]. Also among MNs, specific subtypes of 
differently affected cells can be identified: oculomotor and Onuf’s nucleus MNs proved to be much 
more resistant to the disease process [29]. Reasons accounting for the selective vulnerability of MN 
populations and, in general, for mechanisms of neurodegeneration remain poorly understood. Several 
pathogenetic mechanisms have been taken into consideration, including impaired RNA metabolism, 
aberrant proteic misfolding, mitochondrial alterations, defective axonal transport, excitotoxicity and 
local inflammation [30,31]. The discovery of causative genes has given new inputs to the field. After 
the first report of ALS causative mutations in the gene encoding the Cu/Zn-dependent antioxidant 
enzyme superoxide dismutase-1 (SOD1) [32], researchers have started to investigate non cell-autonomous 
mechanisms linked to the development of ALS disease (i.e., the role of the oxidative damage). The 
identification of C9ORF72 repeat expansion as the major factor responsible for ALS onset  
in the familial forms has focused attention on the causative role of alterations in RNA  
metabolism [33–35], a line of research supported also by the involvement of mutations in TARDBP 
and FUS genes (encoding DNA/RNA binding proteins) in ALS development [36]. 
The establishment of human cell platforms has allowed for the first time to test in vitro some of 
these pathogenetic hypotheses and to model and investigate early disease mechanisms. Eggan’s group 
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pioneered the field in 2008, when they investigated the potential of human MNs derived from 
embryonic stem cells (ESCs) to provide key data on ALS pathogenesis [37]. ESC-derived human MNs 
were cultured on primary cortical glia obtained from SOD1 mutated mice. After 10 days in culture, a 
significant decrease in MN number could be observed in a time-dependent manner, thus suggesting a 
strong implication of non-cell autonomous mechanisms in ALS onset. Moreover, they tested if the 
same toxic glial effect could be detected with human interneurons and they found that the  
glia-induced toxicity is rather specific for MNs: interneurons treated for 20 days with SOD1G93A  
glia-conditioned medium appeared fully preserved. Complementary, MNs co-cultured with 
SOD1G93A mouse embryonic fibroblasts remained unaffected, thus indicating that the toxic effect is 
specifically related to the presence of astrocytes. Oligonucleotide arrays were exploited to identify 
genes differentially expressed in mutant glia. After these analyses, Di Giorgio and colleagues focused 
their investigation on the role of prostaglandin D2, which resulted responsible for a significant 
decrease of MN survival in culture. This work proved the advantages to use human cells for in vitro 
disease studies and provided the basis for further investigations on ALS pathogenesis. 
The same research group proceeded beyond these results with a recent study aiming to elucidate 
pathways which are impaired by the expression of mutated SOD1 in human MNs [26]. Kiskinis and 
colleagues derived iPSCs from skin fibroblasts of ALS patients; these cells harbored the  
patient-specific genetic combination, thus providing a precious tool to model the development of 
human pathology. Human iPSCs were differentiated towards MNs and compared with two healthy 
human iPSC lines. Diseased MN number decreased in culture in a time-dependent manner, a process 
that did not affect the non-motor neuronal cells present in the plate. Both control and SOD1 iPSC lines 
presented a further reduced survival when co-cultured with SOD1 glia, but this effect was much more 
amplified in the latter case implying the presence of a strong cell-autonomous component in ALS 
pathology. SOD1 MNs presented also an unhealthy morphology with shorter processes and reduced 
soma, thus summarizing the changes observed in the human pathology. Importantly, ZFN-mediated 
gene correction of SOD1 mutation resulted in the rescue of both altered morphology and reduced 
lifespan. Data from RNA-seq of SOD1 MNs highlighted a strong down-regulation of genes related to 
mitochondria functions and protein translation. Further analyses showed impairment in mitochondria 
motility in addition to an enrichment of mitochondria number located in neuronal processes. A substrate 
of ER stress has been found in healthy human MNs, which could be related to the cell size; this result is 
in line with the well-known early degeneration of largest alpha MNs in ALS. A combination of oxidative 
and ER stress and the up-regulation of the unfolded protein response (UPR) have been shown and could 
be additive causative mechanisms of neuronal toxicity. Moreover, the electrical activity of MNs could be 
involved in the ER stress, a result which nicely correlates with the report of the intrinsic hyperexcitability 
displayed by iPSCs-derived MNs from ALS patients [38]. Finally, comparison between human-iPSCs 
derived C9ORF72 and SOD1 lines led to the discovery of common pathways downstream of these 
mutations related to enhanced oxidative stress response and decreased mitochondria activity. 
C9ORF72 iPSC lines were obtained by Sareen et al. to investigate the pathological processes 
underlying the most common genetic form of ALS [39]. They investigated whether the toxicity linked 
to the repeat expansion in C9ORF72 was due to either gain of function or loss of function or both 
mechanisms. To address this question, iPSCs lines were developed from different C9ORF72 
hexanucleotide expansion carriers affected by ALS and/or frontotemporal lobar degeneration (FTLD). 
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Southern blot analyses were performed on derived MNs assessing the expansion and also highlighting 
differences among patients, which in some cases could be reflected in more severe forms of the 
disease. FISH analyses detected the presence of RNA foci within C9ORF72-ALS MNs (and also in the 
neuronal progenitors and astrocytes), in line with previous data from patients’ tissues [40]. Observed 
RNA foci co-localized with Pur-alpha and hnRNAP1 but not with FUS or TDP43, responsible for 
other genetic forms of ALS. However, hnRNAP1 is known to interact with TDP43 [41] and its 
involvement in the disease process could suggest an indirect connection between C9ORF72 and 
TDP43 ALS forms. This work provided data in the direction of a “gain of function” mechanism linked 
to C9ORF72 hexanucleotide expansion. It has been shown that the mutated allele is usually transcribed 
and its downregulation using antisense oligonucleotides did not affect cell viability, but resulted in the 
correction of cell transcriptional profile. The specific pathogenetic role of the involvement of different 
RNA binding proteins interacting with RNA foci needs further investigations and could represent a 
common causative mechanism shared by different forms of ALS. Indeed, the aberrant cytoplasmatic 
aggregation of TDP43 represents a rather common pathological hallmark both in familial and sporadic 
ALS. Processes leading from the cytoplasmic aggregation to the selective MN loss appear to be 
exquisitely human and not easily detectable in animal models, where overexpression of TDP43 is 
ubiquitously provoked. Indeed, the majority of cell platforms and animal models considered in ALS 
pathogenesis studies relied on the overexpression of TDP43 in nonhuman or nonneuronal cells. 
Reason underlying the selective vulnerability of MNs to the disease process could be misled as well as 
the investigation of key molecular events that cause the human disease [40]. The establishment of human 
iPSC-derived platforms has allowed significant advances in the field. Bilican et al. generated iPSCs 
from a patient affected by ALS carrying the TDP43 M337V mutation and used them as a tool to 
investigate TDP43 pathology in human neuronal cells [42]. No differences in the differentiation and 
maturation towards a motor neuronal fate could be observed between TDP43-iPSCs and healthy 
controls. However, affected MNs presented reduced survival in culture and higher levels of soluble 
and detergent-resistant TDP43, probably due to an alteration in post-translational mechanisms. 
Interestingly, mutant MNs appeared to be vulnerable to PI3K inhibition, while they were not affected 
by inhibitors of other kinase pathways. This suggests also a specificity in the neuronal response to 
different neurotrophic factors involved in PI3K rather than MAPK pathways. The role of 
neurotrophines in the survival of TDP43 MNs is worthy of further investigation and this work opened 
up the path to the use of TDP43-ALS patients’ iPSCs as a valid disease model. 
Alami et al. proceeded beyond these data to elucidate the role of TDP43 in physiological conditions 
and its impairment in ALS related disease [43]. Using at first a Drosophila model, they discovered that 
TDP43 cytoplasmatic granules are motile and dynamically transported along axons. Further studies in 
murine cortical neurons showed that this transport is microtubule-dependent and resulted in impaired 
in TPD43 mutated neurons, where granules appeared more immotile and often reversed direction. 
Other forms of axonal transport, such as mitochondria movement, were unaffected, thus suggesting a 
selective function and, consequently, alteration of TDP43 granules. These granules were found to be 
directly involved in the transport of specific mRNAs, such as Neurofilament-L (NEFL) mRNA, along 
the axons. To avoid influences related to the overexpression of TDP43 in the animal models, these 
results needed to be validated in patients’ iPSC-derived MNs. NEFL transport was analyzed in iPSC-MNs 
derived from patients carrying the same mutations studied in Drosophila and murine neurons (M337V 
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and A315T) plus G298S. An impairment of the anterograde transport of NEFL granules was 
demonstrated together with an increase of retrograde movement. It is also important to highlight that 
TDP43 domain affected by the mutation is a prion-like domain known to be involved in the assembly 
of RNA granules. This study provided important data on a physiological function of TDP43 
cytoplasmatic granules and how their impairment could significantly contribute to ALS pathology. 
Neurofilament aggregation is a well-known pathological hallmark of ALS. Thanks to iPSC-based 
technology, Chen et al. could investigate the causative role of mutant SOD1 in impairing 
neurofilament (NF) turnover within MNs [44]. To bypass concerns related to heterogeneity among 
individuals, they generated ALS patients’ iPSCs and used transcription activator-like effector 
nucleases (TALEN) technology to correct the D90ASOD1 mutation, thus obtaining isogenic controls. 
A modified differentiation protocol was applied to originate synchronized mature cells avoiding the 
generation of later-born MNs or glial cells. 
Indeed, challenges that need to be overcome when producing iPSC-derived neurons involve both 
the generation of immature cells and significant differences in the time rate of differentiation among 
iPSC colonies. These issues could lead to the production of heterogonous populations in terms of 
neural differentiated phenotype. The optimization of differentiation protocols has allowed generating 
neural cell populations that are synchronized regarding their growth in culture, in order to properly 
observe and investigate all the phases of their development [42]. 
NF subunits in ALS-MNs appeared to be unbalanced and developed a tendency to aggregate 
leading to neurite degeneration, an effect that probably interests the early phases of the disease in vivo 
when patients present phenotypically asymptomatic or with very mild symptoms. This effect was due 
to the presence of mutated SOD1, as demonstrated by gain of function and loss of function 
experiments. Further analyses revealed that binding of SOD1 to 3′ UTR of NF-L mRNA could cause 
the alteration of NF structure, making them prone to aggregate. These events were selectively present 
in ALS-MNs and not in control cells or non-MNs. Moreover, human ALS MNs presented in vitro 
lower/normal levels of SOD1 (and increased amount of NF) compared to control MNs, strongly 
contrasting data from animal models where mutant SOD1 levels are much higher. 
Overall, these results highlight the importance of validating data obtained from animal models in 
human cells and using them as a precious tool to elucidate mechanisms which are peculiar of human 
physiology and pathology. The identification of the mechanisms underlying the development of ALS 
is crucial for the discovery of new therapeutic compounds. Indeed, the elucidation of the role of 
misregulated neurofilament turnover [44], granular impaired trafficking [43] rather than the 
mitochondrial dysfunction [26], together with other recent discoveries [45], may be a key moment in 
the identification of specific molecular targets for the development of effective therapies. Most likely, 
an effective therapeutic approach should be as comprehensive as possible to counteract the multiple 
aspects of ALS multifactorial pathogenesis. Certainly, the use of human cells for disease modeling  
in vitro has provided crucial data for this purpose (Table 1). The optimization of iPSC-based platforms 
can also represent an effective tool for in vitro screening of potential therapeutic compounds 
previously identified [46]. Finally, it is worth mentioning that Kondo et al. reported very recently how 
local transplants of human iPSC-derived glial-rich neural progenitors (hiPSC-GRNPs) were able to 
reduce MN degeneration and increase lifespan in a murine model of mutant SOD1 ALS [47].  
ALS astrocytes are known to contribute to neuroinflammation and neuronal death within the spinal cord.  
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HiPSC-GRNPs represent a renewable source of autologous cells able to give rise to healthy astrocytes, which can provide trophic support to endogenous 
diseased MNs. Kondo and colleagues observed an improvement of ALS pathology even when hiPSC-GRNPs were transplanted after the disease onset 
(the most probable clinical setting) thus providing evidence that glia cells could play a major role in ALS pathogenesis and, eventually, therapy. 
Table 1. iPSC-Based studies on amyotrophic lateral sclerosis/spinal muscular atrophy (ALS/SMA) pathogenesis. 
Reference Cells 
Reprogramming 
Method 
Differentiation Protocol Mechanism 
Di Giorgio  
et al. 2008 
[37] 
Human  
ESC-derived MNs 
- 
Human ESC media without FGF2 or plasmanate + RA (Sigma)  
(1 μM) and an agonist of the SHH signaling pathway (1 μM) in 
N2 media: 1:1 DMEM:F12 + Glutamate (Gibco), penicillin 
(10,000 units) and streptomycin (Gibco) (1 mg/mL), N2 
Supplement (Gibco) (1%), AA (Sigma-Aldrich) (0.2 mM),  
D-(+)-Glucose (Sigma-Aldrich) (0.16%), BDNF (R&D)  
(10 ng/mL), for 14 days. 
MNs co-cultured with SOD1G93A astrocytes undergo 
cell death. 
Prostaglandin D2 is responsible for the decrease in 
MN survival. 
Kiskinis  
et al. 2014 
[26] 
Fibroblasts  
from SOD1A4V 
ALS patients → 
iPSC-derived MNs 
Retroviral 
transduction 
(KLF4, SOX2, 
OCT4,  
and c-MYC) 
DMEM/F12, KSR (15%) on days 1–4; 
SOD1 iPSCs and MNs suffer a reduction in survival 
when co-cultured with SOD1 glia. SOD1 MNs exhibit 
shorter processes and reduced soma. Gene correction 
of SOD1 mutation rescues both morphology and 
survival. 
DMEM/F12 with L-glutamine, NEAAs, HE (2 μg/mL), N2 
supplement (Gibco) on days 5–24; 
SOD1 MNs show a down-regulation of genes implied 
in mitochondria homeostasis. 
SB431542 (Sigma) (10 μM) + DM (Segment) (1 μM) on  
days 1–6; 
Oxidative and ER stress and the up-regulation of UPR 
may contribute to neuronal toxicity. 
BDNF (R&D) (10 ng/mL), AA (Sigma) (0.4 mg/mL), RA 
(Sigma) (1 μM) and SAG 1.3 (Calbiochem) (1 μM) on  
days 5–24. 
C9ORF72 and SOD1 MNs share common disrupted 
pathways leading to enhanced  
oxidative stress response and decreased mitochondria 
activity. 
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Table 1. Cont.  
Reference Cells 
Reprogramming 
Method 
Differentiation Protocol Mechanism 
Sareen et al. 
2013 [39] 
Fibroblasts from 
C9ORF72  
ALS patients → 
iPSC-derived MNs 
Episomal plasmid 
nucleofection 
(OCT4, SOX2, 
KLF4, L-MYC, 
LIN28, and  
p53 shRNA) 
IMDM supplemented with B27-vitamin A (2%) and N2 
(1%) on days 1–6; 
RNA foci in C9ORF72 MNs co-localize with 
hnRNAP1, suggesting an indirect connection between 
C9ORF72 and TDP43 ALS forms. 
addition of all-trans RA (0.1 μM) on days 6–25; The toxicity linked to C9ORF72 hexanucleotide 
expansion may be due to a “gain of  
function” mechanism. 
Neurobasal, B27 (2%) and N2 (1%) + RA (0.1 μM) and 
PMN (1 μM) on days 17–25; 
DMEM/F12, B27 (2%), RA (0.1 μM), PMN (1 μM),  
db-cAMP (1 μM), AA (200 ng/mL), BDNF (10 ng/mL), and 
GDNF (10 ng/mL) for a further 2–7 weeks; 
The downregulation of the mutated allele with 
antisense oligonucleotides corrects the cell 
transcriptional profile. 
Bilican et al. 
2012 [42] 
Fibroblasts from 
TDP43 M337V 
ALS patients → 
iPSC-derived MNs 
Retroviral 
transduction  
(KLF4, SOX2, 
OCT4, and c-MYC)
Chemically defined medium supplemented with SB431542 
(Tocris) (10 μM), DM (Calbiochem) (2.5 μM), and NAC 
(Sigma) (0.5 μM) for 5–7 days; 
TDP43 MNs present a reduced survival in culture and 
high levels of TDP43 due to aberrant  
post-translational mechanisms. chemically defined medium with RA (Sigma) (0.1 μM) for  
7–12 days; 
Neurobasal medium (Invitrogen), RA (0.1 μM), PMN 
(Calbiochem) (1 μM), N2 supplement (Invitrogen) (1%), 
NEAAs (Invitrogen) (1%), penicillin/streptomycin 
(Invitrogen) (1%), GlutaMAX (Invitrogen) (1%), and basic 
FGF (5 ng/mL) for 7–10 days; 
Neuronal response to neurotrophic factors involved in 
PI3K pathways influences TDP43 MN survival. 
Neurobasal medium (Invitrogen), N2 supplement 
(Invitrogen) (0.5%), NEAAs (Invitrogen) (1%), 
penicillin/streptomycin (Invitrogen) (1%), GlutaMAX 
(Invitrogen) (0.5%), BDNF (PeproTech) (10 ng/mL), GDNF 
(PeproTech) (10 ng/mL), and F (Tocris) (10 μM) for  
3–6 weeks. 
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Table 1. Cont. 
Reference Cells 
Reprogramming 
Method 
Differentiation Protocol Mechanism 
Alami et al. 
2014 [43] 
Fibroblasts from 
TDP43 A315T and 
TPD43 G298S ALS 
patients →  
iPSC-derived MNs 
Retroviral 
transduction (OCT4, 
SOX2, and KLF4) 
KSR medium (KO-DMEM (Life Technologies) 
supplemented with KSR (Life Technologies) (15%),  
1 × Gibco GlutaMAX (Life Technologies) and NEAAs  
(100 μM) on days 0–10; The microtubule-dependent transport of NEFL mRNA 
granules along the axon is impaired in TDP43 MNs. 
N2 medium (Neurobasal (Life Technologies)) supplemented 
with 1 × N2 (Life Technologies), 1X Gibco GlutaMAX (Life 
Technologies) and NEAAs (100 μM)) on days 4–14; 
SB431542 (Sigma) (10 μM) and LDN-193189 (Segment) 
(100 nM) on days 0–5; 
TDP43 domain affected by the mutation is involved in 
the assembly of RNA granules. 
RA (Sigma) (1 μM), SAG (EMD Millipore) (1 μM), DAPT 
(EMD Millipore) (5 μM) and SU-5402 (Biovision) (4 μM) 
on days 2–14; 
murine glia-conditioned N2 medium supplemented with  
1 × B-27 (Life Technologies), and BDNF (10 ng/mL), 
GDNF (10 ng/mL) and CNTF (R&D) (10 ng/mL). 
Chen et al. 
2014 [44] 
Fibroblasts from 
SOD1A4V and 
SOD1D90A ALS 
patients →  
iPSC-derived MNs 
Non-integrating 
Sendai virus 
transduction 
(OCT3/4, SOX2, 
KLF4, and c-MYC)
DMEM/F12, N2 supplement, NEAAs, SB431542 (2 μM), 
LDN193189 (300 nM), and CHIR99021 (3 μM, all from 
Stemgent, Cambridge, MA, USA) on days 1–7; 
Binding of SOD1 to 3′ UTR of NF-L mRNA may be 
responsible for neurofilament tendency to aggregate 
leading to neurite degeneration. 
addition of RA (0.1 μM) and PMN (0.5 μM) on days 8–14; Unlike mice SOD1 MNs, human SOD1 MNs have 
lower or normal levels of SOD1 compared to  
control MNs. 
DMEM/F12, N2 supplement, and NEAAs on days 14–21. 
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Table 1. Cont. 
Reference Cells 
Reprogramming 
Method 
Differentiation Protocol Mechanism 
Ebert et al. 
2009 [48] 
Fibroblasts from a 
SMN1 SMA type I 
patient →  
iPSC-derived MNs 
Lentiviral 
transduction (OCT4, 
SOX2, NANOG, and 
LIN28) 
NIM (1:1 DMEM/F12 and N2 supplement (Gibco) (1%)) 
supplemented with RA (0.1 μM) for 1 week; 
SMA iPSCs show reduced levels of SMN full-length 
transcripts, due to SMN1 loss, and a few truncated 
transcripts lacking exon 7. 
addition of SHH (R&D) (100 ng/mL) for 1 week; 
After a robust production, SMA iPSC-derived MNs 
undergo a reduction in number and size compared to 
WT iPSC-derived MNs. 
RA and SHH medium supplemented with cAMP (1 mM), 
AA (200 ng/mL), BDNF and GDNF (both 10 ng/mL,  
PeproTech Inc., Rocky Hill, USA) for 2–6 weeks. 
MN ontogenesis in SMA is disrupted by  
post-development damage. 
Sareen et al. 
2012 [49] 
Fibroblasts from a 
SMN1 SMA  
type I patient → 
iPSC-derived MNs 
Episomal plasmid 
nucleofection 
(OCT4, SOX2, 
NANOG,  
and LIN28) 
Stemlin Neural Expansion Media (Sigma) supplemented 
with EGF (100 g/mL), FGF-2 (100 ng/mL), and HE  
(5 μg/mL) for 3 weeks; 
SMA MNs show increased levels of cleaved  
caspase-3 and caspase-8 and membrane-bound Fas 
ligand, suggesting that apoptosis is implied in MN 
dysfunction and loss in SMA. 
NIM (1:1 DMEM/F12 and N2 (1%)) in the presence of  
all-trans RA (0.1 μM) for 1 week; The administration of Anti Fas-Ab rescues MN 
survival in in vitro models of SMA. 
addition of PMN (1 μM) or SHH (10 ng/mL) for 1–3 weeks. 
Corti et al. 
2012 [20] 
Fibroblasts from 
SMN1 SMA type I 
patients →  
iPSC-derived MNs 
Episomal plasmid 
nucleofection 
(OCT4, SOX2, 
NANOG, LIN28,  
c-MYC, and KLF4)
DMEM/F12 (Gibco, Invitrogen), supplemented with MEM 
NEAAs solution, N2, and HE (Sigma-Aldrich) (2 mg/mL) 
for 10 days; 
SMA MNs show a reduction in size, axonal 
elongation, neuromuscular junction production and 
overall decreased survival. 
addition of RA (Sigma-Aldrich) (0.1 μM) for 7 days; 
SMA MNs exhibit a different splicing profile in a 
subset of genes encoding proteins involved in RNA 
metabolism, MN differentiation, axonal guidance and 
signal transduction. 
same medium with RA (0.1 μM) and SHH (R&D)  
(100–200 ng/mL) for 7 days; 
Gene correction of SMN2 with antisense 
oligodeoxynucleotides rescues the cellular damage 
and the altered splicing profile secondary to SMN1 
deficiency in vitro. 
addition of BDNF, GDNF, and IGF-1 (PeproTech)  
(10 ng/mL) on day 24. 
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Table 1. Cont. 
Reference Cells 
Reprogramming 
Method 
Differentiation Protocol Mechanism 
McGivern  
et al. 2013 
[50] 
Fibroblasts from  
SMN1 SMA  
patients →  
iPSC-derived glia 
Lentiviral transduction 
(OCT4, SOX2, NANOG, 
and LIN28); Episomal 
plasmid nucleofection 
(OCT4, SOX2, NANOG, 
LIN28) 
Human neural progenitor growth medium (Stemline,  
Sigma-Aldrich) supplemented with basic FGF-2 
(Chemicon) (100 ng/mL), EGF (Chemicon) (100 ng/mL), 
and HE (Sigma-Aldrich) (5 μg/mL); 
SMA astrocytes show increased basal calcium levels 
with a minimal response to ATP and an activated state 
that precedes MN loss. 
DMEM: Nutrient Mixture F12 (Invitrogen) supplemented 
with B27 (Invitrogen) (2%) with or without CNTF for  
2–8 weeks. 
The ERK apoptosis pathways of SMA MNs may be 
initiated by the defective calcium homeostasis and the 
deficiency of trophic factors. 
AA = Ascorbic Acid; BDNF = Brain-Derived Neurotrophic Factor; cAMP = cyclic Adenosine MonoPhosphate; CNTF = Ciliary Neurotrophic Factor;  
DAPT = Difluorophenacetyl-Alanyl-Phenylglycine-T-butyl ester; DM = Dorsomorphin; DMEM = Dulbecco’s Modified Eagle Medium; EGF = Epidermal Growth Factor; 
F = Forskolin; FGF-2 = Fibroblasts Growth Factor-2; GDNF = Glial cell line-Derived Neurotrophic Factor; HE = Heparin; IGF-1 = Insulin-like Growth Factor-1;  
IMDM = Iscove’s Modified Dulbecco’s Medium; KSR = Knock-out Serum Replacement; NAC = N-Acetyl-Cysteine; NEAAs = Non-Essential Amino Acids;  
NIM = Neural Induction Medium; PMN = Purmorphamine; RA = Retinoic Acid; SAG = Smoothened Agonist; SHH = Sonic Hedgehog. 
3. Modeling and Studying Spinal Muscular Atrophy Using IPSCs 
Ebert and Svendsen were the first authors to demonstrate that human iPSCs can be employed to recapitulate the specific pathology that underlies  
SMA [48]. Until then, the only models available for research purposes on the disease were provided by worms, flies and mice, which presented considerable 
limitations, including technical constraints like the necessity of performing complicated knockout strategies. Similarly, human fibroblasts did not prove to 
be suitable for the study of the disease mechanisms and the screening of new drug compounds, since the SMN protein presents features that are peculiar 
to neural line-belonging cells. Applying lentiviral infection methods, SMA iPSCs were generated from fibroblasts of a 3 years old boy affected by  
type I SMA. Wild-type (WT) iPSCs derived from fibroblasts of his unaffected mother served as controls. Through RT-PCR analysis, that was  
performed in both WT and SMA iPSCs and fibroblasts in order to assess SMN mRNA, WT-iPSCs turned out to have comparable levels of SMN to  
WT fibroblasts, while SMA iPSCs showed significantly reduced levels of SMN full-length transcripts, as a result of the loss of SMN1 gene.  
RT-PCR analysis also detected a few truncated transcripts lacking exon 7, along with the full-length SMN transcripts, witnessing the maintenance of 
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functional SMN2 gene and its alternative splicing. Since lower alpha MNs are the main target of the 
pathological processes of SMA, iPSCs from SMA and WT fibroblasts were directed towards a motor 
neuronal and glial fate, in order to disclose in which phase of maturation the pathogenetic events 
occur. If in the early stages of the differentiation protocol a robust production of MNs was described 
and no significant difference was documented between the SMA- and WT-derived MNs, interestingly, 
around week 10 of the protocol, the SMA-derived MNs appeared to be decreased both from a 
quantitative and a qualitative point of view, as they were fewer and smaller compared to the  
WT-derived MNs. It was then speculated that the SMA phenotype hampers MN ontogenesis at later 
developmental time periods, either by inhibiting the generation of new cells or increasing the 
degeneration of those already matured. This was the first study to report that human iPSCs can be 
adopted as a reliable model of a genetically inherited disease, such as SMA, and serve as a powerful 
tool for a better understanding of its etiopathogenesis. 
Sareen and Svendsen’s group carried on the experiment for a more precise definition of the 
mechanisms that are responsible for the post-developmental damage that leads to cell death, as 
observed in vitro [49]. Sareen and colleagues generated two lines of iPSCs from two patients affected 
by SMA type I and one line of control iPSCs, and then differentiated them into MNs. The first results 
were consistent with the previous work: after a normal production of MNs at 4 weeks into the 
differentiation protocol, the cell population underwent a selective reduction in number and size 
compared to the control iPSC-derived MN cultures. The group ascribed this degeneration to the 
activation of apoptosis pathways, as suggested by the significantly high percentage of apoptotic cells 
after 7–10 weeks of differentiation. In particular, the assay of increased levels of apoptotic markers at 
8 weeks of differentiation, namely cleaved caspase-3 and caspase-8, supported the assumption that 
apoptosis plays a crucial role in cell death in SMA iPSCs-derived MN cultures. The intracellular 
apoptotic signaling cascade is known to be initiated by caspase-8, triggered by the binding of  
Fas-ligands to their receptors (a TNF family transmembrane protein) [51]. This was confirmed by 
increased levels of membrane-bound Fas ligand in SMA MNs after 6 weeks of differentiation. The 
next step was to evaluate whether the inhibition of the Fas-receptor apoptotic pathway could rescue the 
degeneration of MNs in the SMA lines: the administration of a monoclonal antibody targeting the  
Fas-receptor (Anti Fas-Ab), starting from the second week of differentiation and for the whole duration 
of the differentiation process, proved to significantly increase the number of MNs in SMA lines at  
8 weeks of differentiation, compared to the untreated cultures [49]. Taken together, these data suggest 
that an iPSCs-based model of SMA not only may provide new insights on the molecular and 
pathological processes behind neuronal dysfunction and loss in SMA, but may also represent an 
invaluable testing ground for the screening and development of new drug compounds, that may 
eventually be beneficial for patients. 
Another contribution to the knowledge on the pathogenic mechanisms of SMA was given by Corti 
and colleagues [20]. Using a viral- and transgene-free method, they reprogrammed fibroblasts of  
two type I SMA patients into iPSCs by nucleofecting them with plasmids encoding pluripotency 
factors (OCT4, SOX2, NANOG, LIN28, c-Myc, and KLF4). A parallel experiment was conducted on 
a subpopulation of the obtained iPSCs that were treated, and therefore genetically corrected, with 
SMN2 sequence-specific oligodeoxynucleotides. The correction of SMA iPSCs consisted in the 
exchange of a T to C at position +6 of exon 7, thus converting SMN2 into SMN1 through the  
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inclusion of exon 7 in SMN2 transcripts. Subsequently, the model required the differentiation of SMA 
fibroblasts-derived iPSCs, both treated and untreated, into MNs, the cell-type majorly involved in 
SMA, in order to evaluate the effects of SMN1 deficiency on these cells. At week 8 of the multistage 
differentiation protocol, based on the administration of Retinoic Acid and Sonic Hedgehog, they 
observed specific disease effects of the SMN1 defect on untreated SMA iPSCs-derived MNs compared 
to the cultures treated with oligodeoxynucleotides. The statistically significant alterations included an 
overall reduction in cell soma size, axonal elongation and in the ability to form neuromuscular 
junctions, resulting in a decreased survival of MNs derived from untreated iPSCs. This experiment 
well demonstrates that a SMA model reproducing at least some aspects of the disease can be 
generated, and that MN dysfunction in SMA is the result of multiple neuropathological events likely 
occurring at a late differentiative state. Genetic correction of SMN2 via oligodeoxynucleotides proved 
to rescue the cellular damage to the defective SMN1 gene and to significantly increase the number of 
detectable gems, nuclear aggregates of SMN protein which correlate with the rate of translation of the  
full-length protein. 
Given the recent hypothesis on the role of RNA and splicing abnormalities as a primary determinant 
of selective MN death in SMA [52,53], the experiment was then directed to the analysis of 
transcriptional changes in untreated SMA iPSC-derived MNs compared to heterozygous iPSC- and 
treated SMA iPSC-MNs. Gene expression and exon array analysis of RNA revealed a different 
splicing profile in a subset of genes encoding transcripts that are considered to play a crucial role in 
SMA pathogenesis, being involved in RNA metabolism, MN differentiation, axonal guidance and 
signal transduction. Remarkably, the molecular correction with oligodeoxynuleotides proved to shift 
most of the genes that are differentially expressed or spliced in SMA iPSC-derived MNs towards the 
heterozygous pattern, further supporting the data on the efficacy of this strategy in correcting the 
alterations secondary to SMN1 deficiency. 
Following the hypothesis that a cell population other than MNs may be implied in the activation of 
the apoptotic cascade, the attention was then focused on glial cells. Indeed, astrocytes had already 
proved to contribute to MN dysfunction in SOD1 mutated models of ALS [54,55] and to play a key 
role as mediators of neurodegeneration in a variety of nosological conditions, including Parkinson’s 
disease [56]. In order to examine morphologic and functional alterations in glial sub-populations, 
Ebert’s group differentiated human SMA-derived iPSCs and WT iPSCs into astrocytes [50], the most 
abundant cell type in the central nervous system, that are supposed to be responsible for the 
maintenance of the perfect environment for neurons’ homeostasis [57]. They described an activated 
phenotype of SMA astrocytes, as shown by the intense cytoplasmic staining of Glial Fibrillary Protein 
(GFAP) and Nestin, two components of intermediate filament proteins that are upregulated in reactive 
glial cells. The activation state was accompanied by significant changes in astrocyte morphology, as 
they displayed enlarged bodies and thick, short processes. The observation that such alterations occur 
in the early stages of the differentiation protocol of SMA-derived iPSCs into astrocytes was crucial to 
infer that the MN loss is preceded by the activation of glial cells, suggesting a causal relationship 
between the two events. The alterations in the phenotype of astrocytes turned out to be the 
epiphenomenon of their functional impairments, as ratiometric live-cell calcium imaging reported 
increased basal calcium levels with a minimal response to ATP in SMA astrocytes compared to WT 
iPSCs-derived astrocytes. The authors concluded that the defective calcium homeostasis may lead to 
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the activation of apoptotic pathways triggered by the upregulation of pERK1/2 in SMA iPSCs-derived 
astrocytes, and the resulting increased expression of proinflammatory cytokines like TNF-alpha, IL-1 
and IL-6. The ERK programmed cell death cascade was speculated to be initiated also by the deficiency of 
trophic factors, as witnessed by a decrease in the secretion of Growth Derived Neurotrophic Factor 
(GDNF), and the whole apoptotic process was attributed to a Fas-mediated mechanism. 
Overall, the possibility to isolate cell types that are specifically damaged in the disease process, like 
MNs and glia cells in SMA, makes iPSCs an unprecedented tool to disclose pathogenetic mechanisms 
that have been inaccessible so far (Table 1). Moreover, the establishment of reliable disease models is 
a fundamental milestone in the process of testing novel therapeutic strategies and finally finding a 
definitive treatment for SMA [58]. 
4. Discussion 
The pathogenesis of several MNDs is still obscure under multiple aspects, thus hampering the 
development of potential therapies [2]. Experimental studies conducted on animal models are crucial, 
but unfortunately results so far are insufficient [2]. Concerning ALS research, it has been found the 
overexpression of SOD1 which characterizes mutant SOD1 mice may influence observed molecular 
phenotypes [59]. With regard to SMA, mice physiologically lack the homologous SMN2 gene, which 
plays a crucial role in determining clinical phenotypes [60]. As a consequence, data derived from 
pathogenetic studies need to be validated in human cellular models. Human ESCs have been largely 
employed for this purpose [37,61], but their use may be limited by ethical issues. Moreover, ESCs are 
not always available in substantial amount for large scale in vitro studies. On the other hand, the 
development of iPSC-based technology has allowed to generate human pluripotent cells in abundance 
to perform any in vitro study bypassing ethical constraints [22]. Furthermore, a great advantage of 
iPSCs is that they carry the genetic combination of an individual, thus permitting the study of  
patient-specific mutations. Issues concerning the heterogeneity of iPSC lines, which could provide 
misleading results, may be overcome by a careful experimental setting. This should be based on 
rigorous statistical analysis and standardized protocols. Moreover, the use of cutting-edge molecular 
methods allows correcting the mutation in patient-derived iPSCs, thus obtaining isogenic controls [44]. 
Another critical issue is represented by reprogramming techniques: reliable results could be obtained 
with the use of non-integrative methods or at least sparing the original cell genotype [20]. It is crucial 
to pay attention to the cellular subtypes obtained in culture with varying differentiation protocols in 
order to avoid misleading results: well established cellular markers need to be used to assess both the 
neuronal phenotype and the maturation state. In addition, several studies have highlighted the 
possibility that reprogrammed cells might maintain an epigenetic memory of the cell of origin, which 
could interfere with the expression of membrane markers [62]. Recently, advances in reprogramming 
methods have led to the possibility of directly differentiating mature cells (i.e., fibroblasts or 
astrocytes) into relevant cell types (i.e., induced neurons) [63]. These rather novel methods are quite 
efficient in reducing time in culture and speed up the differentiation protocol, but need further 
assessment. It also needs to be pointed out that pathogenesis studies benefit from long-term 
observation, from the cell pluripotent state to the mature phenotype, in order to speculate on the  
time-dependent disease alteration. 
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5. Conclusions 
The development and optimization of iPSC-based platforms has allowed elucidating disease-specific 
mechanisms, which are exquisitely human (Figure 1). Further advances may finally open up the path to 
a full understanding of key pathogenetic events, leading to the development of effective treatments for 
ALS, SMA and other MNDs. 
Acknowledgments 
Cariplo grant to SC 2012-0513. 
The support of Associazione Amici del Centro Dino Ferrari is gratefully acknowledged. 
Author Contributions 
We confirm that all authors have participated in the writing of the manuscript (Irene Faravelli and 
Emanuele Frattini conceived the idea, revised all the literature and contributed to all parts;  
Giulia Stuppia revised the literature regarding ALS, and Agnese Ramirez revised the literature 
regarding SMA; Monica Nizzardo and Stefania Corti supervised and critically revised the manuscript, 
contributed to the revision of online websites and editing).  
Conflicts of interest 
The authors declare no conflict of interest. 
References 
1. McDermott, C.J.; Shaw, P.J. Diagnosis and management of motor neurone disease. BMJ 2008, 
336, 658–662. 
2. Gordon, P.H. Amyotrophic lateral sclerosis: An update for 2013 clinical features, 
pathophysiology, management and therapeutic trials. Aging Dis. 2013, 4, 295–310. 
3. Patten, S.A.; Armstrong, G.A.; Lissouba, A.; Kabashi, E.; Parker, J.A.; Drapeau, P. Fishing for 
causes and cures of motor neuron disorders. Dis. Model. Mech. 2014, 7, 799–809. 
4. Rafiq, M.K.; Proctor, A.R.; McDermott, C.J.; Shaw, P.J. Respiratory management of motor 
neurone disease: A review of current practice and new developments. Pract. Neurol. 2012, 12, 
166–176. 
5. Kiernan, M.C.; Vucic, S.; Cheah, B.C.; Turner, M.R.; Eisen, A.; Hardiman, O.; Burrell, J.R.; 
Zoing, M.C. Amyotrophic lateral sclerosis. Lancet 2011, 377, 942–955. 
6. Finsterer, J.; Burgunder, J.M. Recent progress in the genetics of motor neuron disease.  
Eur. J. Med. Genet. 2014, 57, 103–112. 
7. Logroscino, G.; Traynor, B.J.; Hardiman, O.; Chio, A.; Mitchell, D.; Swingler, R.J.;  
Millul, A.; Benn, E.; Beghi, E. Incidence of amyotrophic lateral sclerosis in europe.  
J. Neurol. Neurosurg. Psychiatry 2010, 81, 385–390. 
J. Clin. Med. 2014, 3 1141 
 
 
8. Beghi, E.; Chio, A.; Couratier, P.; Esteban, J.; Hardiman, O.; Logroscino, G.; Millul, A.;  
Mitchell, D.; Preux, P.M.; Pupillo, E.; et al. The epidemiology and treatment of als: Focus on the 
heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph. Lateral Scler. 
2011, 12, 1–10. 
9. Al-Chalabi, A.; Hardiman, O. The epidemiology of ALS: A conspiracy of genes, environment and 
time. Nat. Rev. Neurol. 2013, 9, 617–628. 
10. Majounie, E.; Renton, A.E.; Mok, K.; Dopper, E.G.; Waite, A.; Rollinson, S.; Chio, A.;  
Restagno, G.; Nicolaou, N.; Simon-Sanchez, J.; et al. Frequency of the C9ORF72 hexanucleotide 
repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A 
cross-sectional study. Lancet Neurol. 2012, 11, 323–330. 
11. Lorson, C.L.; Rindt, H.; Shababi, M. Spinal muscular atrophy: Mechanisms and therapeutic 
strategies. Hum. Mol. Genet. 2010, 19, doi:10.1093/hmg/ddq147. 
12. Prior, T.W.; Snyder, P.J.; Rink, B.D.; Pearl, D.K.; Pyatt, R.E.; Mihal, D.C.; Conlan, T.; Schmalz, B.; 
Montgomery, L.; Ziegler, K.; et al. Newborn and carrier screening for spinal muscular atrophy. 
Am. J. Med. Genet. A 2010, 152A, 1608–1616. 
13. Russman, B.S. Spinal muscular atrophy: Clinical classification and disease heterogeneity.  
J. Child Neurol. 2007, 22, 946–951. 
14. Lefebvre, S.; Burlet, P.; Liu, Q.; Bertrandy, S.; Clermont, O.; Munnich, A.; Dreyfuss, G.;  
Melki, J. Correlation between severity and smn protein level in spinal muscular atrophy.  
Nat. Genet. 1997, 16, 265–269. 
15. Monani, U.R.; Lorson, C.L.; Parsons, D.W.; Prior, T.W.; Androphy, E.J.; Burghes, A.H.; 
McPherson, J.D. A single nucleotide difference that alters splicing patterns distinguishes the SMA 
gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999, 8, 1177–1183. 
16. Vitte, J.; Fassier, C.; Tiziano, F.D.; Dalard, C.; Soave, S.; Roblot, N.; Brahe, C.; Saugier-Veber, P.; 
Bonnefont, J.P.; Melki, J.; et al. Refined characterization of the expression and stability of the 
smn gene products. Am. J. Pathol. 2007, 171, 1269–1280. 
17. Wang, C.H.; Finkel, R.S.; Bertini, E.S.; Schroth, M.; Simonds, A.; Wong, B.; Aloysius, A.; 
Morrison, L.; Main, M.; Crawford, T.O.; et al. Consensus statement for standard of care in spinal 
muscular atrophy. J. Child Neurol. 2007, 22, 1027–1049. 
18. Wee, C.D.; Kong, L.; Sumner, C.J. The genetics of spinal muscular atrophies. Curr. Opin. Neurol. 
2010, 23, 450–458. 
19. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult 
fibroblast cultures by defined factors. Cell 2006, 126, 663–676. 
20. Corti, S.; Nizzardo, M.; Simone, C.; Falcone, M.; Nardini, M.; Ronchi, D.; Donadoni, C.;  
Salani, S.; Riboldi, G.; Magri, F.; et al. Genetic correction of human induced pluripotent  
stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 2012, 4, 
doi:10.1126/scitranslmed.3004108. 
21. Chipman, P.H.; Toma, J.S.; Rafuse, V.F. Generation of motor neurons from pluripotent stem 
cells. Prog. Brain Res. 2012, 201, 313–331. 
J. Clin. Med. 2014, 3 1142 
 
 
22. Sandoe, J.; Eggan, K. Opportunities and challenges of pluripotent stem cell neurodegenerative 
disease models. Nat. Neurosci. 2013, 16, 780–789. 
23. Kondo, T.; Asai, M.; Tsukita, K.; Kutoku, Y.; Ohsawa, Y.; Sunada, Y.; Imamura, K.; Egawa, N.; 
Yahata, N.; Okita, K.; et al. Modeling alzheimer’s disease with ipscs reveals stress phenotypes 
associated with intracellular abeta and differential drug responsiveness. Cell Stem Cell 2013, 12, 
487–496. 
24. Camnasio, S.; Delli Carri, A.; Lombardo, A.; Grad, I.; Mariotti, C.; Castucci, A.; Rozell, B.;  
Lo Riso, P.; Castiglioni, V.; Zuccato, C.; et al. The first reported generation of several induced 
pluripotent stem cell lines from homozygous and heterozygous huntington’s disease patients 
demonstrates mutation related enhanced lysosomal activity. Neurobiol. Dis. 2012, 46, 41–51. 
25. Chung, C.Y.; Khurana, V.; Auluck, P.K.; Tardiff, D.F.; Mazzulli, J.R.; Soldner, F.; Baru, V.;  
Lou, Y.; Freyzon, Y.; Cho, S.; et al. Identification and rescue of alpha-synuclein toxicity in 
parkinson patient-derived neurons. Science 2013, 342, 983–987. 
26. Kiskinis, E.; Sandoe, J.; Williams, L.A.; Boulting, G.L.; Moccia, R.; Wainger, B.J.; Han, S.;  
Peng, T.; Thams, S.; Mikkilineni, S.; et al. Pathways disrupted in human ALS motor neurons 
identified through genetic correction of mutant SOD1. Cell Stem Cell 2014, 14, 781–795. 
27. Miller, R.G.; Brooks, B.R.; Swain-Eng, R.J.; Basner, R.C.; Carter, G.T.; Casey, P.; Cohen, A.B.; 
Dubinsky, R.; Forshew, D.; Jackson, C.E.; et al. Quality improvement in neurology: Amyotrophic 
lateral sclerosis quality measures: Report of the quality measurement and reporting subcommittee 
of the american academy of neurology. Neurology 2013, 81, 2136–2140. 
28. Tovar, Y.R.L.B.; Ramirez-Jarquin, U.N.; Lazo-Gomez, R.; Tapia, R. Trophic factors as modulators 
of motor neuron physiology and survival: Implications for ALS therapy. Front. Cell. Neurosci. 
2014, 8, doi:10.3389/fncel.2014.00061. 
29. Brockington, A.; Ning, K.; Heath, P.R.; Wood, E.; Kirby, J.; Fusi, N.; Lawrence, N.;  
Wharton, S.B.; Ince, P.G.; Shaw, P.J.; et al. Unravelling the enigma of selective vulnerability in 
neurodegeneration: Motor neurons resistant to degeneration in als show distinct gene expression 
characteristics and decreased susceptibility to excitotoxicity. Acta Neuropathol. 2013, 125,  
95–109. 
30. Sreedharan, J.; Brown, R.H., Jr. Amyotrophic lateral sclerosis: Problems and prospects.  
Ann. Neurol. 2013, 74, 309–316. 
31. Vucic, S.; Rothstein, J.D.; Kiernan, M.C. Advances in treating amyotrophic lateral sclerosis: 
Insights from pathophysiological studies. Trends Neurosci. 2014, 37, 433–442. 
32. Rosen, D.R.; Sapp, P.; O’Regan, J.; McKenna-Yasek, D.; Schlumpf, K.S.; Haines, J.L.;  
Gusella, J.F.; Horvitz, H.R.; Brown, R.H., Jr. Genetic linkage analysis of familial amyotrophic 
lateral sclerosis using human chromosome 21 microsatellite DNA markers. Am. J. Med. Genet. 
1994, 51, 61–69. 
33. DeJesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; 
Nicholson, A.M.; Finch, N.A.; Flynn, H.; Adamson, J.; et al. Expanded GGGGCC hexanucleotide 
repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 
2011, 72, 245–256. 
J. Clin. Med. 2014, 3 1143 
 
 
34. Su, X.W.; Broach, J.R.; Connor, J.R.; Gerhard, G.S.; Simmons, Z. Genetic heterogeneity of 
amyotrophic lateral sclerosis: Implications for clinical practice and research. Muscle Nerve 2014, 
49, 786–803. 
35. Ling, S.C.; Polymenidou, M.; Cleveland, D.W. Converging mechanisms in ALS and FTD: 
Disrupted RNA and protein homeostasis. Neuron 2013, 79, 416–438. 
36. Renton, A.E.; Chio, A.; Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics.  
Nat. Neurosci. 2014, 17, 17–23. 
37. Di Giorgio, F.P.; Boulting, G.L.; Bobrowicz, S.; Eggan, K.C. Human embryonic stem cell-derived 
motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation.  
Cell Stem Cell 2008, 3, 637–648. 
38. Wainger, B.J.; Kiskinis, E.; Mellin, C.; Wiskow, O.; Han, S.S.; Sandoe, J.; Perez, N.P.;  
Williams, L.A.; Lee, S.; Boulting, G.; et al. Intrinsic membrane hyperexcitability of amyotrophic 
lateral sclerosis patient-derived motor neurons. Cell Rep. 2014, 7, 1–11. 
39. Sareen, D.; O’Rourke, J.G.; Meera, P.; Muhammad, A.K.; Grant, S.; Simpkinson, M.; Bell, S.; 
Carmona, S.; Ornelas, L.; Sahabian, A.; et al. Targeting RNA foci in iPSC-derived motor  
neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 2013, 5, 
doi:10.1126/scitranslmed.3007529. 
40. Renton, A.E.; Majounie, E.; Waite, A.; Simon-Sanchez, J.; Rollinson, S.; Gibbs, J.R.;  
Schymick, J.C.; Laaksovirta, H.; van Swieten, J.C.; Myllykangas, L.; et al. A hexanucleotide 
repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 
72, 257–268. 
41. Buratti, E.; Brindisi, A.; Giombi, M.; Tisminetzky, S.; Ayala, Y.M.; Baralle, F.E. TDP-43 binds 
heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail J. Biol. Chem. 2005, 280, 
37572–37584. 
42. Bilican, B.; Serio, A.; Barmada, S.J.; Nishimura, A.L.; Sullivan, G.J.; Carrasco, M.; Phatnani, H.P.; 
Puddifoot, C.A.; Story, D.; Fletcher, J.; et al. Mutant induced pluripotent stem cell lines 
recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. 
Acad. Sci. USA 2012, 109, 5803–5808. 
43. Alami, N.H.; Smith, R.B.; Carrasco, M.A.; Williams, L.A.; Winborn, C.S.; Han, S.S.; Kiskinis, E.; 
Winborn, B.; Freibaum, B.D.; Kanagaraj, A.; et al. Axonal transport of TDP-43 mRNA granules 
is impaired by ALS-causing mutations. Neuron 2014, 81, 536–543. 
44. Chen, H.; Qian, K.; Du, Z.; Cao, J.; Petersen, A.; Liu, H.; Blackbourn, L.W., IV; Huang, C.L.; 
Errigo, A.; Yin, Y.; et al. Modeling als with ipscs reveals that mutant SOD1 misregulates 
neurofilament balance in motor neurons. Cell Stem Cell 2014, 14, 796–809. 
45. Poppe, L.; Rue, L.; Robberecht, W.; van Den Bosch, L. Translating biological findings  
into new treatment strategies for amyotrophic lateral sclerosis (ALS). Exp. Neurol. 2014, 
doi:10.1016/j.expneurol.2014.07.001. 
46. Egawa, N.; Kitaoka, S.; Tsukita, K.; Naitoh, M.; Takahashi, K.; Yamamoto, T.; Adachi, F.; 
Kondo, T.; Okita, K.; Asaka, I.; et al. Drug screening for ALS using patient-specific induced 
pluripotent stem cells. Sci. Transl. Med. 2012, 4, doi:10.1126/scitranslmed.3004052. 
J. Clin. Med. 2014, 3 1144 
 
 
47. Kondo, T.; Funayama, M.; Tsukita, K.; Hotta, A.; Yasuda, A.; Nori, S.; Kaneko, S.; Nakamura, M.; 
Takahashi, R.; Okano, H.; et al. Focal transplantation of human iPSC-derived glial-rich neural 
progenitors improves lifespan of als mice. Stem Cell Rep. 2014, 3, 242–249. 
48. Ebert, A.D.; Yu, J.; Rose, F.F., Jr.; Mattis, V.B.; Lorson, C.L.; Thomson, J.A.; Svendsen, C.N. 
Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457,  
277–280. 
49. Sareen, D.; Ebert, A.D.; Heins, B.M.; McGivern, J.V.; Ornelas, L.; Svendsen, C.N. Inhibition of 
apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. 
PLoS One 2012, 7, e39113. 
50. McGivern, J.V.; Patitucci, T.N.; Nord, J.A.; Barabas, M.E.; Stucky, C.L.; Ebert, A.D. Spinal 
muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor 
production. Glia 2013, 61, 1418–1428. 
51. Lafont, E.; Milhas, D.; Teissie, J.; Therville, N.; Andrieu-Abadie, N.; Levade, T.; Benoist, H.; 
Segui, B. Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase 
inhibitor zVAD-fmk. PLoS One 2010, 5, e13638. 
52. Zhang, Z.; Lotti, F.; Dittmar, K.; Younis, I.; Wan, L.; Kasim, M.; Dreyfuss, G. SMN deficiency 
causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in 
splicing. Cell 2008, 133, 585–600. 
53. Baumer, D.; Lee, S.; Nicholson, G.; Davies, J.L.; Parkinson, N.J.; Murray, L.M.; Gillingwater, T.H.; 
Ansorge, O.; Davies, K.E.; Talbot, K.; et al. Alternative splicing events are a late feature of 
pathology in a mouse model of spinal muscular atrophy. PLoS Genet. 2009, 5, e1000773. 
54. Brites, D.; Vaz, A.R. Microglia centered pathogenesis in als: Insights in cell interconnectivity. 
Front. Cell. Neurosci. 2014, 8, 117, doi:10.3389/fncel.2014.00117. 
55. Benkler, C.; Ben-Zur, T.; Barhum, Y.; Offen, D. Altered astrocytic response to activation in 
SOD1(G93A) mice and its implications on amyotrophic lateral sclerosis pathogenesis. Glia 2013, 
61, 312–326. 
56. Hirsch, E.C.; Hunot, S.; Hartmann, A. Neuroinflammatory processes in parkinson’s disease.  
Park. Relat. Disord. 2005, 11 (Suppl. 1), 9–15. 
57. Wang, D.D.; Bordey, A. The astrocyte odyssey. Prog. Neurobiol. 2008, 86, 342–367. 
58. Garbes, L.; Heesen, L.; Holker, I.; Bauer, T.; Schreml, J.; Zimmermann, K.; Thoenes, M.;  
Walter, M.; Dimos, J.; Peitz, M.; et al. VPA response in sma is suppressed by the fatty acid 
translocase CD36. Hum. Mol. Genet. 2013, 22, 398–407. 
59. Van Den Bosch, L. Genetic rodent models of amyotrophic lateral sclerosis. J. Biomed. Biotechnol. 
2011, 2011, doi:10.1155/2011/348765. 
60. Schmid, A.; DiDonato, C.J. Animal models of spinal muscular atrophy. J. Child Neurol. 2007, 22, 
1004–1012. 
61. Re, D.B.; Le Verche, V.; Yu, C.; Amoroso, M.W.; Politi, K.A.; Phani, S.; Ikiz, B.; Hoffmann, L.; 
Koolen, M.; Nagata, T.; et al. Necroptosis drives motor neuron death in models of both sporadic 
and familial ALS. Neuron 2014, 81, 1001–1008. 
J. Clin. Med. 2014, 3 1145 
 
 
62. Vaskova, E.A.; Stekleneva, A.E.; Medvedev, S.P.; Zakian, S.M. “Epigenetic memory” 
phenomenon in induced pluripotent stem cells. Acta Naturae 2013, 5, 15–21. 
63. Hermann, A.; Storch, A. Induced neural stem cells (iNSCs) in neurodegenerative diseases.  
J. Neural Transm. 2013, 120 (Suppl. 1), 19–25. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
